InvestSMART

Botanix Pharmaceuticals Ltd (ASX:BOT)

ALERT: Price-sensitive ASX Announcement for BOT
Current share price for BOT : $0.021 -0.003 (-12.50%)+
Announcement
Release
13 Jul 2026 9:13AM
Price at Release
$0.024
Full Release
download
Summary
Botanix Pharmaceuticals Ltd has received a Notice of Allowance from the United States Patent and Trademark Office for a US patent application related to the crystalline form of sofpironium bromide, the active ingredient in their drug Sofdra. This patent will provide additional intellectual property protection for Sofdra, which is used to treat primary axillary hyperhidrosis in patients aged nine years and older. The patent is expected to extend the protection of Sofdra’s drug substance until May 2040, strengthening Botanix’s strategic focus on their intellectual property portfolio.
Key Points
  • Botanix Pharmaceuticals Ltd received a Notice of Allowance for a US patent covering Sofdra.
  • The patent relates to the crystalline form of sofpironium bromide.
  • Sofdra is FDA-approved for treating primary axillary hyperhidrosis.
  • The patent provides protection until May 2040.
  • Botanix emphasizes strengthening its intellectual property estate.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.